









Markets
/
Stocks
/
nasdaq-ispc
/

iSpecimen Inc

ISPC

0.330USD

-0.015-4.38%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.22MMarket Cap

LossP/E TTM



iSpecimen Inc

0.330

-0.015-4.38%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of iSpecimen Inc

Currency: USD Updated: 2026-02-06

Key Insights

iSpecimen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 259 out of 482 in the Software & IT Services industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

iSpecimen Inc's Score

Industry at a Glance

Industry Ranking

259 / 482

Overall Ranking

532 / 4521

Industry

Software & IT Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

iSpecimen Inc Highlights

StrengthsRisks

iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.29M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.29M.

Overvalued

The company’s latest PE is -0.04, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 349.56K shares, increasing 39.04% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 29.41K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of iSpecimen Inc is 5.18, ranking 467 out of 482 in the Software & IT Services industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 106.59K, representing a year-over-year decrease of 96.00%, while its net profit experienced a year-over-year decrease of 93.12%.

Score

Industry at a Glance

Previous score

5.18

Change



Financials

6.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

2.39

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.06

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

iSpecimen Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of iSpecimen Inc is 7.24, ranking 312 out of 482 in the Software & IT Services industry. Its current P/E ratio is -0.04, which is -21.09% below the recent high of -0.03 and -3741.00% above the recent low of -1.62.

Score

Industry at a Glance

Previous score

7.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 259/482

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for iSpecimen Inc. The Software & IT Services industry's average is 7.60.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of iSpecimen Inc is 2.17, ranking 469 out of 482 in the Software & IT Services industry. Currently, the stock price is trading between the resistance level at 0.42 and the support level at 0.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.16

Change

0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Neutral

RSI(14)

44.989

Neutral

STOCH(KDJ)(9,3,3)

19.493

Neutral

ATR(14)

0.055

Low Volatility

CCI(14)

58.005

Neutral

Williams %R

85.898

Oversold

TRIX(12,20)

-0.192

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.339

Sell

MA10

0.345

Sell

MA20

0.347

Sell

MA50

0.379

Sell

MA100

0.649

Sell

MA200

0.887

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of iSpecimen Inc is 3.00, ranking 280 out of 482 in the Software & IT Services industry. The latest institutional shareholding proportion is 3.58%, representing a quarter-over-quarter increase of 104.60%. The largest institutional shareholder is James Simons, holding a total of 153.46K shares, representing 1.57% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Renaissance Technologies LLC

Star Investors

153.46K

Virtu Americas LLC

63.26K

OBF Investments LLC

42.10K

+0.00%

Geode Capital Management, L.L.C.

41.69K

+181.52%

Scientech Research LLC

29.49K

The Vanguard Group, Inc.

Star Investors

29.41K

+2277.28%

Wolf (James G)

25.25K

-36.14%

Jane Street Capital, L.L.C.

20.26K

BlackRock Institutional Trust Company, N.A.

2.83K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Software & IT Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of iSpecimen Inc is 1.38, ranking 443 out of 482 in the Software & IT Services industry. The company's beta value is 1.83. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.